PUNE, India, March 2, 2016 /PRNewswire/ --

ReportsandReports.com adds "Duchenne Muscular Dystrophy - Pipeline Review, H2 2015" to its store, with comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.

Complete report on H2 2015 pipeline review of Duchenne Muscular Dystrophy with 66 market data tables and 16 figures, spread across 284 pages is available at http://www.reportsnreports.com/reports/453484-duchenne-muscular-dystrophy-pipeline-review-h2-2015.html .

The report also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Duchenne Muscular Dystrophy Pipeline Review, H2 2015 report include Acceleron Pharma, Inc., Asklepios BioPharmaceutical, Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Capricor Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Debiopharm International S.A., Dong-A Socio Group, Editas Medicine, Inc., Eli Lilly and Company, EryDel SPA, FibroGen, Inc., Galapagos NV, Genethon, GTx, Inc., Idera Pharmaceuticals, Inc., Italfarmaco S.p.A., La Jolla Pharmaceutical Company, Marathon Pharmaceuticals, LLC, Marina Biotech, Inc., Merck KGaA, MyoTherix Inc., NicOx S.A., Nippon Shinyaku Co., Ltd., nLife Therapeutics, S.L., Nobelpharma Co., Ltd., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., Prothelia, Inc., PTC Therapeutics, Inc., ReveraGen BioPharma, Inc., Sanofi, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Shire Plc, Summit Therapeutics Plc, Taiho Pharmaceutical Co., Ltd. and Zambon Company S.p.A.

Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453484 .

Drug profile discussed in this research report are AAV1-Foliistatin, ACE-083, alisporivir, Antisense Oligonucleotide for Duchenne Muscular Dystrophy, Antisense Oligonucleotide to Activate Dystrophin for Duchene Muscular Dystrophy, Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD, Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy, Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy, Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders, arbekacin, ARM-210, AT-300, ataluren, Biostrophin, BMN-044, BMN-045, BMN-053, BMS-986089, CAP-1002, CAT-1004, CAT-1040, CAT-1041, DA-4210, deflazacort, dexamethasone sodium phosphate, domagrozumab, drisapersen, Drug for Duchenne Muscular Dystrophy, Drugs for Duchenne Muscular Dystrophy, DT-200, eteplirsen, FG-3019, Gene Therapy for Duchenne Muscular Dystrophy, Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies, Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy, givinostat, Gtx-027, halofuginone hydrobromide, IB-DMD, idebenone, IMO-8400, LJPC-30Sa, LJPC-30Sb, MG-53, MP-101, Myomir, naproxcinod, NBD Peptide, NS-065, , Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy, Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy, OSX-200, PB-1046, poloxamer, PRO-052, PRO-055, PRT-01, PRT-20, Recombinant Protein for Muscular Dystrophy, Recombinant Protein to Activate Utrophin for Muscular Dystrophies, Recombinant Proteins for Duchenne Muscular Dystrophy, rimeporide, RTC-13, SHP-619, Small Molecule for Duchenne Muscular Dystrophy, Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy, Small Molecules for Duchenne Muscular Dystrophy, Small Molecules to Target Utrophin for Duchenne Muscular Dystrophy, SMT-022357, SMTC-1100, SRP-4008, SRP-4044, SRP-4045, SRP-4050, SRP-4052, SRP-4053, SRP-4055, Stem Cell Therapy for Duchenne Muscular Dystrophy, Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy, Stryka-516, Stryka-969, StrykaPro-1, SYN-01, tadalafil, TAS-205, TVN-102, TXA-127, Verolone and ZP-049.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports